Unfortunately, no.

Although many cancer vaccines are now being studied, so far, none has been approved by the US Food and Drug Administration, said Jeffrey Schlom, [cq], chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute.

And when they are approved, they will be aimed not at preventing disease, like the flu and polio vaccines, but to keep cancer from coming back after treatment.

Cancer vaccines are “therapeutic,” that is they are designed to rev up the immune system to fight a cancer that’s already present, or to keep the immune system primed to notice and fight any cancer cells that recur.

There are vaccines to prevent some viral infections that can lead to cancer. There is an approved vaccine against hepatitis B, and an experimental vaccine against hepatitis C; both viruses are associated with liver cancer. And there is a promising vaccine against HPV, human papilloma virus, which is associated with cervical cancer.

For the cancers not associated with viruses, researchers are designing vaccines designed to directly attack proteins called antigens on the surface of cancer cells. Sometimes, the same antigens pop up in diverse malignancies – breast cancer, lung cancer and colorectal cancer, which means that the same vaccine could be used against all these. In other cases, cancer cells carry a unique antigen, which means a special vaccine would have to be developed just against that cancer. In still other cases, researchers are also working on individualized vaccines that would attack antigens unique not just to the cancer but to the particular person.

Among the more promising vaccines are those to fight melanoma, the deadly skin cancer, said Dr. Stephen Hodi, clinical director of the melanoma program at Boston’s Dana-Farber Cancer Institute. There are dozens of such melanoma vaccines now in clinical trials, though one vaccine has been approved in Canada. (Melacine)

As the therapeutic vaccines become approved and widely used, researchers believe it will be important to give them soon after a patient’s initial treatment with surgery, radiation or chemotherapy is over – before the cancer has time to come back in force.